Ginwa Enterprise (Group) Inc. Class A

Ginwa Enterprise (Group) Inc. Class A

SSSE:600080
3.65
CNY
-0.07
(-1.88%)
-0.16EPS
1.72BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.54
2.34
2.39
2.18
2.13
2.14
2.04
1.95
1.47
1.56
1.51
1.64
1.54
1.49
Basic EPS, GAAP
0.15
0.1
0.08
0.09
0.15
0.11
0.07
0.11
-0.05
0.09
-0.11
0.21
0.04
-0.15
Free Cash Flow per Basic Share
0.11
0.05
0.06
0.09
-0.01
0.07
0.13
0.11
0.05
0.06
-0.02
-0.59
-0.28
- -
Dividend per Share
0.03
0.03
- -
- -
0.05
0.06
0.05
0.04
0.1
- -
0.01
0.01
0.04
- -
Book Value per Share
3.27
3.34
3.42
3.51
3.66
4.64
4.59
4.61
4.44
4.51
4.39
4.18
4.18
4.17
Tangible Book Value per Share
3.1
3.16
3.26
3.34
3.37
4.41
4.37
4.38
4.2
4.28
4.16
3.96
3.89
3.87
Basic Weighted Avg Shares
305
305
305
305
356
348
370
343
363
372
373
357
352
355
Sales/Revenue/Turnover
471
713
730
667
757
745
755
668
534
579
565
585
544
530
Operating Margin (%)
7.61
3.81
3.54
6.04
6.07
4.78
4.26
0.92
1.34
1.12
-1.02
4.39
0.98
0.39
Depreciation Expense
26
26
25
26
26
26
25
28
28
30
38
19
19
- -
Net Income, GAAP
46
31
25
27
53
38
26
38
-18
33
-43
75
16
-54
Effective Tax Rate (%)
- -
3.84
19.77
35.78
15.25
12.51
36.76
20.13
- -
30.15
- -
- -
17.44
- -
Profit Margin (%)
9.68
4.34
3.48
4.09
7.06
5.14
3.43
5.65
-3.4
5.78
-7.59
12.74
2.86
-10.27
Working Capital
194
218
267
21
48
701
701
695
702
676
755
415
295
227
LT Debt
- -
- -
- -
- -
- -
- -
50
- -
- -
12
5
9
3
9
Total Equity
998
1,020
1,046
1,074
1,118
1,733
1,716
1,721
1,656
1,684
1,638
1,559
1,558
1,556
Return on Invested Capital (%)
- -
2.65
2.23
2.16
2.71
2.47
1.51
1.96
- -
0.71
- -
- -
0.92
- -
Return on Capital (%)
- -
2.68
2
2.4
4.8
3.08
1.54
2.34
- -
2.04
- -
- -
1.24
- -
Return on Common Equity (%)
4.66
3.07
2.46
2.58
4.88
2.69
1.5
2.2
-1.08
2
-2.58
4.66
1
- -

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
49
83
84
LT Borrowings
- -
- -
- -
LT Finance Leases
10
9
9
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
373
373
373
Market Capitalization
3,188
1,669
1,721

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
600
586
547
Cash, Cash Equivalents & STI
332
318
267
Accounts Receivable, Net
118
113
108
Inventories
35
40
39
Total Current Liabilities
301
325
320
Payables & Accruals
- -
- -
- -
ST Debt
49
83
84
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
5.14%
-1.94%
-0.07%
Free Cash Flow
160.04%
425.44%
-52.37%
Net Income, GAAP
-92.53%
-202.73%
-79.12%
Sales/Revenue/Turnover
-2.44%
-3.5%
-7.07%
Total Cash Common Dividend
- -
- -
307.48%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
116
130
173
167
585
2025
107
134
- -
160
544
2026
127
119
124
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.06
-0.04
0.06
0.12
0.21
2025
- -
0.01
- -
-0.05
0.04
2026
0.01
-0.01
-0.1
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
0.01
0.01
2025
0.01
0.02
- -
- -
0.04
2026
- -
- -
- -
- -
- -

Company Description

CEO
Zhuo Jun Han
Full Time Employees
613
Sector
Health technology
Industry
Pharmaceuticals: major
Address
South Building Xi'an SA China 710075
IPO Date
Jun 12, 1997
Business
Ginwa Enterprise (Group) Inc. Ginwa Enterprise (Group) Inc. engages principally in the research, development, production, and sale of pharmaceuticals in China. The company offers a range of products including orthopedic medicines such as Jintiange capsules; immune products like Jinhua brand transfer factor capsules and transfer factor oral liquid; pediatric, antibiotic, digestive system, gynecological, cardiovascular, antipyretic, analgesic, antiviral, and other therapies; as well as chemical drugs, proprietary Chinese medicines, raw materials, and health-related products in forms including tablets, capsules, granules, powders, mixtures, oral solutions, syrups, and external solutions. It operates primarily in the healthcare sector with a focus on biopharmaceuticals, proprietary Chinese medicines, and chemicals, targeting domestic markets through its complete drug R&D, production, and sales system, and also engages in pharmaceutical logistics, hotel services, and rental business. Ginwa Enterprise (Group) Inc. , founded in 1996 and headquartered in Xi'an, Shaanxi Province, China, maintains 588 employees and conducts its operations across China. Recent developments include the completion in 2024 of a share repurchase program involving 20,557,582 shares for CNY 149.49 million; the 100% equity transfer of Jinhua International Hotel Co., Ltd.; cancellation of the board of supervisors and amendments to the articles of association; director resignations and elections including employee representatives; cancellation and re-pledging of controlling shareholder shares; and in November 2025, a controlling shareholder equity transfer agreement involving acting-in-concert parties.